China's YishengBio chronicles comeback story in Hong Kong IPO while plotting big moves in infectious diseases, cancer
It can be tough to be a vaccine developer in China.
YishengBio shed some light on the regulatory hoops and hurdles it had to jump …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
